More on PTEO
Financials
News
Click line-items for a historical chart and %
| Cash and cash equivalents | 148.14K |
| Research supplies | 100.13K |
| Prepaid expenses and other current assets | 13.57K |
| [AssetsCurrent] | 352.29K |
| PROPERTY AND EQUIPMENT, NET | 7.24K |
| [Assets] | 359.53K |
| Accounts payable and accrued liabilities | 168.44K |
| Accrued licensing fees | |
| [LiabilitiesCurrent] | 335.3K |
| Accrued licensing fees | 639.04K |
| [LiabilitiesNoncurrent] | 752.07K |
| Non-voting preferred stock, par value $0.001 per share; 10,000,000 shares authorized; 694,590 shares and 661,500 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively | 724 |
| Common stock, par value $0.001 per share; 300,000,000 shares authorized; 23,879,350 shares issued and outstanding | 23.88K |
| Additional paid-in capital | 8.99M |
| Note receivable for sale of preferred stock | |
| Accumulated other comprehensive income | 19.68K |
| Deficit accumulated during development stage | |
| Total Proteo, Inc. Stockholders' Equity | -727.84K |
| Nonconrolling Interest | |
| Total Stockholders' Equity | |
| Total Liabilities and Stockholders' Equity | 359.53K |
